Portal de Periódicos da CAPES

Intravenous lacosamide for treatment of absence status epilepticus in genetic generalized epilepsy: A case report and review of literature

2018; Wiley; Volume: 138; Issue: 3 Linguagem: Inglês

10.1111/ane.12935

1600-0404

Philipp S. Reif, Annika Männer, Laurent M. Willems, L.A. Kay, Johann Philipp Zöllner, Karl Martin Klein, Felix Rosenow, Adam Strzelczyk,

Genomics and Rare Diseases

Acta Neurologica ScandinavicaVolume 138, Issue 3 p. 259-262 CLINICAL COMMENTARY Intravenous lacosamide for treatment of absence status epilepticus in genetic generalized epilepsy: A case report and review of literature P. S. Reif, Corresponding Author P. S. Reif philipp.reif@kgu.de orcid.org/0000-0002-9119-8088 Epilepsy Center Frankfurt Rhine-Main and Department of Neurology, Goethe-University, Frankfurt am Main, Germany Correspondence P. S. Reif, Epilepsy Center Frankfurt Rhine-Main, Department of Neurology, J. W. Goethe-University Frankfurt, Frankfurt am Main, Germany. Email: philipp.reif@kgu.deSearch for more papers by this authorA. Männer, A. Männer Epilepsy Center Frankfurt Rhine-Main and Department of Neurology, Goethe-University, Frankfurt am Main, GermanySearch for more papers by this authorL. M. Willems, L. M. Willems Epilepsy Center Frankfurt Rhine-Main and Department of Neurology, Goethe-University, Frankfurt am Main, GermanySearch for more papers by this authorL. Kay, L. Kay Epilepsy Center Frankfurt Rhine-Main and Department of Neurology, Goethe-University, Frankfurt am Main, GermanySearch for more papers by this authorJ. P. Zöllner, J. P. Zöllner Epilepsy Center Frankfurt Rhine-Main and Department of Neurology, Goethe-University, Frankfurt am Main, GermanySearch for more papers by this authorK. M. Klein, K. M. Klein Epilepsy Center Frankfurt Rhine-Main and Department of Neurology, Goethe-University, Frankfurt am Main, GermanySearch for more papers by this authorF. Rosenow, F. Rosenow Epilepsy Center Frankfurt Rhine-Main and Department of Neurology, Goethe-University, Frankfurt am Main, GermanySearch for more papers by this authorA. Strzelczyk, A. Strzelczyk Epilepsy Center Frankfurt Rhine-Main and Department of Neurology, Goethe-University, Frankfurt am Main, GermanySearch for more papers by this author P. S. Reif, Corresponding Author P. S. Reif philipp.reif@kgu.de orcid.org/0000-0002-9119-8088 Epilepsy Center Frankfurt Rhine-Main and Department of Neurology, Goethe-University, Frankfurt am Main, Germany Correspondence P. S. Reif, Epilepsy Center Frankfurt Rhine-Main, Department of Neurology, J. W. Goethe-University Frankfurt, Frankfurt am Main, Germany. Email: philipp.reif@kgu.deSearch for more papers by this authorA. Männer, A. Männer Epilepsy Center Frankfurt Rhine-Main and Department of Neurology, Goethe-University, Frankfurt am Main, GermanySearch for more papers by this authorL. M. Willems, L. M. Willems Epilepsy Center Frankfurt Rhine-Main and Department of Neurology, Goethe-University, Frankfurt am Main, GermanySearch for more papers by this authorL. Kay, L. Kay Epilepsy Center Frankfurt Rhine-Main and Department of Neurology, Goethe-University, Frankfurt am Main, GermanySearch for more papers by this authorJ. P. Zöllner, J. P. Zöllner Epilepsy Center Frankfurt Rhine-Main and Department of Neurology, Goethe-University, Frankfurt am Main, GermanySearch for more papers by this authorK. M. Klein, K. M. Klein Epilepsy Center Frankfurt Rhine-Main and Department of Neurology, Goethe-University, Frankfurt am Main, GermanySearch for more papers by this authorF. Rosenow, F. Rosenow Epilepsy Center Frankfurt Rhine-Main and Department of Neurology, Goethe-University, Frankfurt am Main, GermanySearch for more papers by this authorA. Strzelczyk, A. Strzelczyk Epilepsy Center Frankfurt Rhine-Main and Department of Neurology, Goethe-University, Frankfurt am Main, GermanySearch for more papers by this author First published: 06 April 2018 https://doi.org/10.1111/ane.12935Citations: 7 Funding information This work was supported by the State of Hesse with a LOEWE-Grant to the CePTER-Consortium. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat Abstract Background Nearly 10 years after its introduction into the market, the significance of lacosamide in genetic generalized epilepsies is still unclear. Its new mode of action may qualify lacosamide as a therapeutic agent in this entity, but only a limited number of cases have been published so far. Aim To describe the efficacy of lacosamide as treatment in a patient with the absence status epilepticus. Method We report on a 28-year-old woman with genetic generalized epilepsy who suffered recurrent absence status epilepticus during video-EEG-monitoring. After treatment failure of first- and second-line medication, lacosamide was administered. The outcome in this patient was evaluated, and a systematic literature review was performed for the use of lacosamide in the absence status epilepticus. Results After application of 400 mg lacosamide intravenously, the absence status epilepticus terminated within 30 minutes. No further seizures or epileptiform discharges reoccurred until the end of video-EEG-Monitoring 3 days later. Conclusions The role of lacosamide as a therapeutic option in patients with the absence status epilepticus is unclear. Only two cases have been reported so far with conflicting results. Further randomized controlled studies are required to validate the relevance of lacosamide as treatment for status epilepticus in genetic generalized and the absence epilepsy. CONFLICTS OF INTEREST COI are stated following the guidelines of the International Journal of Clinical Practice (Graf et al. 2007, Best Practice Guidelines on Publication Ethics: a Publisher's Perspective, Int J Clin Pract, 2007:61(152);1-26). P. S. Reif, A. Männer, L. Kay and J. P. Zöllner report no conflicts of interest. L. M. Willems reports travel grants by Eisai. K. M. Klein reports grants and fees by UCB Pharma, Eisai und Novartis. F. Rosenow reports personal fees from Eisai, grants and personal fees from UCB Pharma, grants and personal fees from Desitin Arzneimittel, grants and personal fees from GW pharma personal fees and other from Novartis, personal fees from Medronic, personal fees from cerbomed, personal fees from Shire, personal fees from the vfa, grants from European Union, and grants from Deutsche Forschungsgemeinschaft. A. Strzelczyk reports personal fees and grants from Desitin Arzneimittel, Eisai, LivaNova, Sage Therapeutics, UCB Pharma, and Zogenix. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines. Citing Literature Volume138, Issue3September 2018Pages 259-262 RelatedInformation